top of page
QuanMol Tech.
Founded Year
2022
Stage
Seed+
Category
AI in Drug Discovery
Website
Committed to transforming the drug development domain, QuanMol's platform equips chemists with the tools to detect less-than-ideal substrates, offering them pragmatic solutions grounded in robust reasoning. Mimicking the process of engaging with experienced peers, QuanMol seamlessly connects theoretical chemistry with real-world application. Harnessing tools such as the Thinker module, the company promotes intuitive interfaces while integrating advanced multi-modeling interaction analytics, solidifying its leadership in drug refinement and molecular studies.
What Founders say
"Joining the H7 Accelerator program, we aspire to forge meaningful partnerships with customers and investors while showcasing our cutting-edge product to the wider community."
Xingyu Shen, Ph.D.
CEO
bottom of page